Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Multi-Cancer Early Detection (MCED)




THE EARLIER THE BETTER

Too often, cancer is detected too late. Current screening tests can find some types of cancer - breast, colon, cervical, and lung - but those make up less than 1/3 of all cancer cases.1 We are working to change this. When cancer is found early, it's more treatable.1 Our goal is to make early cancer detection part of routine healthcare.

OUR TEST

Multi-cancer early detection (MCED) is a new kind of blood test that can find cancer at its earliest stages, when it's most treatable. MCED can find many types of cancer, including those with no screening methods today. We're designing our MCED test to fit into routine medical care, alongside current standard cancer screening tools.

To support our test, we’re developing a complete set of services that include result interpretation, follow-up testing, and care coordination. Exact Sciences will be a partner for healthy patients, cancer patients, and doctors along the testing journey.

DETECT-A STUDY

DETECT-A2 was the first ever prospective, interventional study of a multi-cancer blood test. An early version of our MCED test was studied among 10,000 women with no prior cancer history. In the study, our blood test more than doubled the number of cancers first found through screening, with 65% of cancers found at earlier stages. The results were published in Science in April 2020. Based on that data, we continue to validate our test in new studies, including those aimed at FDA approval. 




1
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin.
2021;71(1):7-33. doi:10.3322/caac.21654.

2 Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science.2020;369(6499). 10.1126/science.abb9601. Jul 3, 2020.